{"id":1020767,"date":"2026-11-12T19:16:58","date_gmt":"2026-11-13T00:16:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-shareholder-notice-cvrx-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-cvrx-class-action-lawsuit\/"},"modified":"2026-11-12T19:16:58","modified_gmt":"2026-11-13T00:16:58","slug":"cvrx-shareholder-notice-cvrx-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-cvrx-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cvrx-shareholder-notice-cvrx-inc-investors-with-substantial-losses-have-opportunity-to-lead-the-cvrx-class-action-lawsuit\/","title":{"rendered":"CVRX SHAREHOLDER NOTICE: CVRx, Inc. Investors with Substantial Losses Have Opportunity to Lead the CVRx Class Action Lawsuit"},"content":{"rendered":"
\n

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Hagens Berman, a national shareholder rights litigation firm, alerts investors in\u00a0CVRx, Inc. (NASDAQ: CVRX)<\/strong> to a class action lawsuit filed in federal court. The filing follows disclosures of a U.S. Department of Justice Civil Investigative Demand (\u201cCID\u201d), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company’s Chief Revenue Officer.<\/p>\n

\n CVRx ,Inc. (NASDAQ: CVRX) Investors:<\/strong> Investors who suffered substantial losses are encouraged to submit your losses now<\/a> to evaluate their legal rights and recovery options.<\/p>\n

\n Class Period: <\/strong>July 25, 2023 \u2013 Aug. 6, 2026
Lead Plaintiff Deadline: <\/strong>Jan. 8, 2026
Visit:<\/strong>www.hbsslaw.com\/cvrx<\/a>
Direct Contact Email: <\/strong>CVRX@hbsslaw.com<\/a>
Firm Telephone: 844-916-0895<\/strong>
Blog: <\/strong>www.hbsslaw.com\/blog\/implantable-devices-and-the-defibrillation-of-reality-cvrx-inc-cvrx<\/strong><\/a><\/p>\n

\n CVRx, Inc. ($CVRX) Securities Class Action<\/strong>\n <\/p>\n

CVRx\u2019s sole commercial product is Barostim, an FDA-approved implantable neuromodulation device designed to improve symptoms for patients suffering from heart failure. Historically, CVRx assured investors that its growth strategy was anchored by a complete sales force transformation and high approval rates from Medicare Advantage payers.\u00a0<\/p>\n

CVRx repeatedly highlighted a \u201c$10.5 billion market opportunity\u201d<\/strong> with less than 1% penetration, reassuring the market earlier this year that its sales force transformation was \u201clargely complete.\u201d<\/p>\n

However, after market close on August 6, 2026<\/strong>, CVRx disclosed a series of severe operational and legal headwinds:<\/p>\n

    \n
  1. \n DOJ Civil Investigative Demand (CID):<\/strong> On May 14, 2026, CVRx received a CID from the U.S. Department of Justice investigating whether the company caused the submission of false claims to government health programs by improperly marketing Barostim, paying kickbacks to healthcare providers, or submitting false information.<\/li>\n
  2. \n Sales Force Deterioration & Guidance Cut:<\/strong> CVRx significantly cut its 2026 revenue expectations and revealed serious problems with its salesforce \u2013 sequentially flat growth in sales territories, turnover, and strained onboarding and training.<\/li>\n
  3. \n Medicare Advantage Approval Collapse:<\/strong> CVRx revealed that its primary Medicare Advantage payer\u2014which historically approved 80%<\/strong> of prior authorizations within 30 days\u2014increased initial denials and reduced 30-day approvals to just 25%<\/strong>.<\/li>\n<\/ol>\n

    In response to these revelations, CVRx\u2019s stock price cratered 60% on August 7, 2026<\/strong>.<\/p>\n

    Three days later, on August 10, 2026<\/strong>, CVRx abruptly terminated its Chief Revenue Officer (CRO), Robert John.\u00a0<\/p>\n

    \n FOCUS OF THE HAGENS BERMAN INVESTIGATION<\/strong>\n <\/p>\n

    \u201cWe are investigating whether CVRx may have misled investors regarding the true state of its commercial sales force and Medicare Advantage reimbursement rates, as the complaint alleges,\u201d said Reed Kathrein<\/strong><\/a>, a Hagens Berman partner.<\/p>\n

    \n WHAT CVRx (CVRX) INVESTORS & WHISTLEBLOWERS CAN DO<\/strong>\n <\/p>\n